Firstly, by employing PD-L1 as a negative predictive biomarker with a dichotomous score (positive and negative), clinicians may be able to avoid the unnecessary toxicity and economic burden associated with immunotherapy in GC or GEJC patients with a negative or low PD-L1 expression [32,33]. This evidence concerns the gene CD274 and gastric cancer.